The United States hereditary angioedema therapeutics market is poised for significant growth, with an expected compound annual growth rate (CAGR) of 8.20% during the forecast period from 2024 to 2032. This growth is primarily driven by advancements in the development of novel therapies, the increasingly favourable regulatory environment, and heightened patient awareness about hereditary angioedema […]
